BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

TRION Pharma Release: Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer


6/6/2011 12:33:21 PM

Munich, Germany, June 6, 2011 / B3C newswire / – TRION Pharma GmbH announces today that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

In about half of the analyzed malignant ascites patients and the majority of gastric cancer patients, a significant increase of antibodies against tumor antigens was observed following the intraperitoneal administration of catumaxomab. In both studies, the antibody response was not restricted to catumaxomab’s target antigen EpCAM, but also included further cancer antigens suggesting the induction of a comprehensive humoral immune response against the individual tumor. Three of four patients who received a second treatment cycle showed an even stronger immune effect, comparable to the booster reaction known from repeated vaccination. In the gastric cancer study, cellular immune response was also analyzed and confirmed. The population of EpCAM-specific peripheral T cells was found to be substantially expanded, four weeks following the treatment.

These new results confirm the drug’s unique capacity to trigger several immune response mechanisms at the same time. Catumaxomab not only induces direct tumor cell destruction – as was presented during last year’s ASCO – but also a long-term vaccination effect against the individual tumor.

“This vaccination effect could provide a decisive advantage over current mono- or bispecific antibody approaches: Permanent treatment with catumaxomab will not be needed” , says Horst Lindhofer, CEO of TRION Pharma. “If we are next able to align these data with clinical outcome, this offers a paradigm shift in antibody-based cancer therapy: From chronic treatment to short-term application with long-term effects. This would lead to significant benefits, not only for cancer patients, but also for public healthcare systems.”

Catumaxomab is marketed by TRION Pharma’s partner Fresenius Biotech for the intraperitoneal treatment of malignant ascites. It is the most advanced representative of TRION Pharma’s unique family of Triomab® antibodies and presently the only approved trifunctional, bispecific antibody on the market world-wide. Three more Triomab® candidates are currently under preclinical or clinical development for the treatment of various cancers.

Triomab ®: Trifunctional antibodies

Triomab® antibodies bind to cancer-associated surface antigens and recruit both T cells as well as accessory cells, such as macrophages, dendritic cells and natural killer cells, to the tumor site. As a result, they provide for a new quality of cancer cell killing, activating both arms of the immune system – the adaptive one with cytotoxic T cells as effectors and the innate one including accessory effector cells. Triomab® antibodies are therefore very effective in destroying cancer cells and show a therapeutic effect at very low doses. Triomab® antibodies are a development of TRION Pharma GmbH. Catumaxomab (Removab®):

Catumaxomab (Removab ®) is the most advanced Triomab® trifunctional antibody (anti-EpCAM x anti-CD3). It received EU market approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas in 2009. Catumaxomab is not only the first drug indicated for the treatment of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide. It is produced by TRION Pharma and marketed by TRION’s partner Fresenius Biotech.

TRION Pharma GmbH is a biopharmaceutical company developing trifunctional antibodies (Triomab®). The trifunctional antibodies are produced at TRION’s site in Munich, Germany , and are based on a proprietary platform technology for which TRION has secured IP rights around the world. For more information please visit the company's website at www.trionpharma.com.

Contact

Dr Dirk Pelster

Chief Operating Officer (COO)

T: +49-89-3242-66-111

F: +49-89-3242-66-199

E: dirk.pelster@trionpharma.de

TRION Pharma GmbH

Frankfurter Ring 193a

80807 Munich, Germany


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->